Indicators
Indicators
Value
Direction
MACD(12,26,9)
-1.551
Neutral
RSI(14)
64.857
Neutral
STOCH(KDJ)(9,3,3)
64.392
Neutral
ATR(14)
8.963
Low Volatility
CCI(14)
66.642
Neutral
Williams %R
22.275
Buy
TRIX(12,20)
1.615
Sell
StochRSI(14)
31.168
Buy
Search
Monopar Therapeutics Inc
MNPRAdd to Watchlist
110.450USD
+0.580+0.53%
Close 07-27 16:00（ET）Quotes delayed by 15 min
739.91MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.53%
5 Days
+4.30%
1 Month
+25.97%
6 Months
+57.13%
Year to Date
+69.14%
1 Year
+145.61%
Key Figures
110.290Open
112.010High
339.77KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
5.07%Turnover Ratio
109.870Prev. Close
106.340Low
16.47MTurnover
LossP/E Static
5.46P/B
0.00%Div Yield TTM
-15.52%ROA
105.00052wk High
1.27Volume Ratio
-15.59MNet Profit
6.70MShares
-1.9313EPS TTM
1.53Beta
-15.86%ROE
28.40052wk Low
5.16%Amplitude
--Gross Margin
739.91MMarket Cap
5.26Reward/Risk
4.81%Risk Rate
TradingKey Stock Score of Monopar Therapeutics Inc
Currency: USD Updated: 2026-07-27Key Insights
Monopar Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 67 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 116.85.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Monopar Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Monopar Therapeutics Inc Highlights
StrengthsRisks
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -57.13, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 5.90M shares, increasing 15.51% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 254.69 shares of this stock.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
116.846
Target Price
+6.35%
Upside Space
Monopar Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
13
analysts
Buy
Current Rating
116.846
Target Price
+6.35%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Monopar Therapeutics Inc
MNPR
13
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
110.390
Buy
MA10
108.597
Buy
MA20
103.599
Buy
MA50
80.526
Buy
MA100
68.625
Buy
MA200
70.787
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Monopar Therapeutics Inc Info
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Ticker SymbolMNPR
CompanyMonopar Therapeutics Inc
CEORobinson (Chandler D)
Websitehttps://www.monopartx.com/
Shareholders
Related Instruments
+0.16%
+0.98%
+0.25%
-0.96%
-0.23%
+0.70%
+0.06%
+1.88%
+0.92%
+0.49%
+0.76%
+0.34%
+1.52%
+1.21%
+1.18%
0.00%
+1.72%
-3.24%
+1.16%
+0.57%Popular Instruments
52258.200
+19.200 (+0.04%)
27760.200
-295.800 (-1.05%)
7396.600
-21.800 (-0.29%)
14707.000
-406.000 (-2.69%)
62361.000
-1444.000 (-2.26%)
6285.700
-25.600 (-0.41%)
80.530
-0.807 (-0.99%)
336.900
+3.880 (+1.17%)
196.560
-10.280 (-4.97%)
4048.430
-28.010 (-0.69%)
FAQs
What is the current price of Monopar Therapeutics Inc (MNPR)?
The current price of Monopar Therapeutics Inc (MNPR) is 110.45.
What is the symbol of Monopar Therapeutics Inc?
The ticker symbol of Monopar Therapeutics Inc is MNPR.
What is the 52-week high of Monopar Therapeutics Inc?
The 52-week high of Monopar Therapeutics Inc is 105.00.
What is the 52-week low of Monopar Therapeutics Inc?
The 52-week low of Monopar Therapeutics Inc is 28.40.
What is the market capitalization of Monopar Therapeutics Inc?
The market capitalization of Monopar Therapeutics Inc is 739.91M.
Is Monopar Therapeutics Inc (MNPR) currently rated as Buy, Hold, or Sell?
According to analysts, Monopar Therapeutics Inc (MNPR) has an overall rating of Buy, with a price target of 116.85.
What is the Earnings Per Share (EPS TTM) of Monopar Therapeutics Inc (MNPR)?
The Earnings Per Share (EPS TTM) of Monopar Therapeutics Inc (MNPR) is -1.85.